Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. - Université de Rennes Accéder directement au contenu
Article Dans Une Revue Trends in Immunology Année : 2011

Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy.

Roch Houot
Holbrook E. Kohrt
  • Fonction : Auteur
Aurélien Marabelle
Ronald Levy
  • Fonction : Auteur correspondant
  • PersonId : 946352

Connectez-vous pour contacter l'auteur

Résumé

Monoclonal antibodies (mAbs) are in widespread use for the treatment of cancer. Their success as cancer therapeutics relies substantially on their ability to engage the immune system. Specifically, Fc-receptor-expressing immune cells mediate the killing of tumor cells by mAbs. Stimulation of these immune effector cells might therefore represent a promising strategy to enhance the therapeutic potential of mAbs. For instance, stimulation of natural killer cells, γδ T cells, macrophages, or dendritic cells can be used to enhance antibody-dependent cellular cytotoxicity, phagocytosis or even tumor vaccine effects. Here, we review several ways to improve the antitumor efficacy of mAbs by combining them with therapies that are directed against immune effector cells.

Domaines

Cancer

Dates et versions

hal-00744044 , version 1 (22-10-2012)

Identifiants

Citer

Roch Houot, Holbrook E. Kohrt, Aurélien Marabelle, Ronald Levy. Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy.. Trends in Immunology, 2011, 32 (11), pp.510-6. ⟨10.1016/j.it.2011.07.003⟩. ⟨hal-00744044⟩
45 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More